

## Special Issue

# Systemic Therapy for Hepatocellular Carcinoma

### Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, also associated with poor prognosis. Novel systemic treatments for intermediate to advanced HCC, including chemotherapy, molecularly targeted therapy, immune checkpoint inhibitor immunotherapy and their combinations, have been evolving rapidly. Furthermore, the efficacies of therapeutic strategies, such as conversion therapy after systemic therapy or a recurrence prevention treatment after curative treatment, have previously been discussed. To improve patient outcomes through the use of well-timed optimal treatments, it is necessary to deepen our knowledge of each treatment and develop novel agents/regimens. This Special Issue aims to review the current literature and provide novel findings regarding systemic therapy mechanisms, biomarkers and strategies for advanced HCC.

---

### Guest Editor

Dr. Atsushi Ono

Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/143296](https://mdpi.com/si/143296)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)